Exploration of Targeted Anti-tumor Therapy

Table 2.

Details of the anticancer efficacy of BD in several human malignancies using in vivo models

Cancer type	Model used	Dose	Duration	Measurement frequency	Route of administration	Observed effects	Mode of action	References
NSCLC	A549 cells in BALB/c-nu mice	40 mg/kg/day	15 days	Every 2 days	Intraperitoneal injection	↓Tumour growth	↑pJNK, ↑caspase 9 ↑Apoptosis; ↑LC3-II, ↑Autophagy	[28]
Osteosarcoma	MNNG/HOS cells in BALC/c-nu mice	2.5 mg/kg/2 days; 5.0 mg/kg/2 days	12 days	Every 2 days	Intraperitoneal injection	↓Tumour size ↓Tumour weight	↓pSTAT3, ↓MMP2 and MMP9, ↓Ki67	[47]
Hepatocellular carcinoma	Huh7 cells in BALC/c-nu mice	0.75 mg/kg/day; 1.5 mg/kg/day	10 days	Daily	Intravenous tail vein injection	↓Tumour growth	↑Proteasome, ↓Total β-catenin, ↓Active β-catenin, ↓JAG1, ↓NICD, ↑Apoptosis	[45]

MMP2: matrix metalloproteinase-2 (gelatinase A); MMP9: matrix metallopeptidase 9 (gelatinase B)